

### **Early Rheumatoid Arthritis**

**Date:** Ongoing

**Location:** 5939 Harry Hines, Suite 441  
Dallas, TX 75235

Have you been told that you have Rheumatoid Arthritis? Rheumatoid Arthritis is a common inflammatory disorder that affects an approximate 1% of the population<sup>1</sup>.

If you have been told less than one year ago that you have Rheumatoid Arthritis, you may be eligible to participate in an international 18 month research study of an investigational combination of medication currently used for Rheumatoid Arthritis.

Eligible participants must:

- Be at least 18 years old
- Have been told by a physician less than 1 year ago that you have Rheumatoid Arthritis
- Have not used previous anti-TNF (Tumor Necrosis Factor) medication including infliximab, etanercept, or adalimumab.
- Have not previously used more than 2 disease modifying anti-rheumatic drugs or have not previously used methotrexate
- Be able to attend a minimum of 14 office visits

Further evaluation at the doctor's office will determine if you are eligible. All study visits and medication will be provided at no charge.

Space is limited, so please call Metroplex Clinical Research Center at 214-424-0407 for additional information or to schedule an appointment.

---

### **Gout**

**Date:** Ongoing

**Location:** 5939 Harry Hines, Suite 441  
Dallas, TX 75235

Do you have Gout?

Pain, swelling, Tenderness in your joints?

Our physicians are conducting a research study to see if an investigational drug can lower uric acid levels in the body (high uric acid can cause gout). If you have a history of gout or are currently experiencing gout symptoms, you may qualify to participate. As a study participant, you will receive all study related care at no charge, including physical exams, lab services and study medication.

To learn how you can join over 2,000 other study participants, call our office today or log on to [www.gouttrial.com](http://www.gouttrial.com)

Metroplex Clinical Research Center  
5939 Harry Hines, Suite 441  
Dallas, Texas 75235  
214-214-0407

[www.gouttrial.com](http://www.gouttrial.com)

---

## **Osteoarthritis of the knee**

**Date:** Ongoing

**Location:** 5939 Harry Hines, Suite 441  
Dallas, TX 75235

Do you feel arthritis pain with every step you take?

If you struggle with pain and stiffness in your knees, you understand the frustration osteoarthritis brings. Taking a walk or climbing a flight of stairs can be a real challenge.

If you're at least 40 years of age and have osteoarthritis of the knee for which you must take pain medication, you may be eligible for a research study of an investigational medication for osteoarthritis. If you qualify, you'll receive study-related physical exams, knee x-ray, ECGs and lab tests.

Take the first step - call to see if you qualify.

**For more information, call:**

214-424-0407

[hswisher@mcrcdallas.com](mailto:hswisher@mcrcdallas.com)

---

## **Lupus**

**Date:** Ongoing

**Location:** 5939 Harry Hines, Suite 441  
Dallas, TX 75235

How do you know if you have lupus nephritis?

If you have lupus and are experiencing symptoms such as blood in your urine, a foamy appearance to your urine, bodily swelling (including face and feet), and elevated blood pressure, you may have lupus nephritis. Lupus nephritis can affect both men and women, but tends to affect more women who are of childbearing age.

If you believe you have lupus nephritis, you may qualify to participate in the LUNAR Study. This Phase III study will help determine the safety and effectiveness of an investigational drug for a large group of patients with lupus nephritis.

**For more information, call:**

214-424-0407

[hswisher@mcrcdallas.com](mailto:hswisher@mcrcdallas.com)

---

## **Rheumatoid Arthritis**

**Date:** Ongoing  
**Location:** Arthritis Care and Diagnostic Center  
8230 Walnut Hill Ln # 818  
Dallas, TX 75231 US

Humira Efficacy Response Optimization Study in Subjects with Active Rheumatoid Arthritis (HERO)

Eligible patients will receive one double-blind injection and then active medication injections every 2 weeks of Humira for 12 weeks. Patients are seen at screening, baseline, weeks 2, 4, and 12. Patients are required to use a hand held electronic palm device daily throughout the study. There is no cost to participate for tests, or for study medication.

Participants must be 18 or older, have Active RA, able to self inject, stable RA medications, no history of biologics, no active infections, no history of cancer or HIV.

### **For more information call:**

Stephanie Pflieghaar  
214.696.1600 ext. 108  
stephanie@albrodskymd.com

---

## **Rheumatoid Arthritis**

**Date:** Ongoing  
**Location:** Arthritis Care and Diagnostic Center  
8230 Walnut Hill Ln # 818  
Dallas, TX 75231 US

A 24-Week, Randomized, Double-Blind Placebo-Controlled, Parallel-Group Study of the Efficacy of Oral SC10-469 in Subjects with Active Rheumatoid Arthritis Who Are Not Receiving DMARDs other than Hydroxychloroquine

Eligible patients who are screened will be randomized to 1 of 4 treatment groups. Follow up appointments approximately every 2 weeks include labwork, ECG, joint exam and questionnaires. Patients take oral study medication 3 times daily with meals in addition to current medications. There is no charge for participation or tests, or study medication.

Participants must be 18 years or older, Active RA, stable NSAIDs and prednisone, no history of cancer or HIV, no current infections, no DMARDs, joint injections or biologics in past 4 weeks.

### **For more information call:**

Stephanie Pflieghaar  
214.696.1600 ext. 108  
stephanie@albrodskymd.com

---

## **Rheumatoid Arthritis**

**Date:** Ongoing  
**Location:** Arthritis Care and Diagnostic Center  
8230 Walnut Hill Ln # 818  
Dallas, TX 75231 US

## A Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Rheumatoid Arthritis

Patients are screened and if eligible will return for 1st injection and will have an MRI of hands, X-ray of hands and feet and DEXA exam. Visits occur at month 1, month 3, month 6 (2nd injection), and month 12. X-rays and DEXA repeated at months 6 and 12. MRI at months 3 and 6. Pt will continue methotrexate throughout study and NSAIDS and prednisone if present at screening, and appropriate.

Patients must be 18 years or older, Active RA, on stable dose of methotrexate for 8 weeks, no biologics in past 8 weeks, no history of cancer, hepatitis or HIV, inability to obtain an MRI or joints replaced in hands or wrist.

### For more information call:

Stephanie Pflieghaar  
214.696.1600 ext. 108  
stephanie@albrodskymd.com

---

## Rheumatoid Arthritis

Date: Ongoing  
Location: UT Southwestern Medical Center  
5323 Harry Hines  
Dallas, TX 75390 US

A 24 Week, Double-Blind, Randomized Study to Determine the Effects of 24 Weeks of Dosing with Tripterygium Wilfordii Hook F (TWHF) or Sulfasalazine in Subjects with Active Rheumatoid Arthritis.

This study is looking at the effectiveness of a Chinese herbal medication (TWHF). The length of the study is 6 months, with approximately 8 visits during the course of the study. All physician visits, lab tests, X-rays, medication and parking costs will be paid by the sponsor. The patient will also receive a modest stipend per visit.

Patients must have a diagnosis of RA for at least 6 months, have active disease and have not taken sulfasalazine in the past for rheumatoid arthritis.

### For more information call:

Valerie Branch, M.S., M.B.A.  
214.648.2018

---

## Do you have Osteoarthritis of the Knee?

Date: Ongoing  
Location: Edinburg, TX

**Purpose of research or disease under study:** To evaluate the efficacy and safety of this medication in patients with pain due to osteoarthritis of the knee.

**Protocol summary (including benefits and time commitment):** Provide significant pain relief associated with osteoarthritis of the knee, free study-related medical tests and treatment, compensation for participation. This is a 26- week (approximately 6.5 month study) consisting of 10 scheduled visits to the clinic.

**Basic eligibility criteria:** Diagnosis of at least 6 months of osteoarthritis of at least one knee experiencing pain.

**For more information call:**

Valeria Sartorio

956-992-7614